-
1
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
-
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833
-
(1998)
J Clin Oncol
, vol.16
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-Lopez, A.J.2
Link, B.K.3
-
2
-
-
13244270361
-
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
-
Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423
-
(2005)
Blood
, vol.105
, pp. 1417-1423
-
-
Marcus, R.1
Imrie, K.2
Belch, A.3
-
3
-
-
63749097149
-
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized Phase III ECOG1496 Study
-
Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614
-
(2009)
J Clin Oncol
, vol.27
, pp. 1607-1614
-
-
Hochster, H.1
Weller, E.2
Gascoyne, R.D.3
-
4
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
5
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391
-
(2006)
Lancet Oncol
, vol.7
, pp. 379-391
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
-
6
-
-
77950478885
-
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
-
Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765
-
(2010)
J Clin Oncol
, vol.28
, pp. 1756-1765
-
-
Robak, T.1
Dmoszynska, A.2
Solal-Celigny, P.3
-
7
-
-
0028835315
-
Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
-
Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-147
-
(1995)
J Clin Oncol
, vol.13
, pp. 140-147
-
-
Johnson, P.W.1
Rohatiner, A.Z.2
Whelan, J.S.3
-
8
-
-
0021703548
-
The natural history of initially untreated low-grade non-Hodgkin's lymphomas
-
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471-1475
-
(1984)
N Engl J Med
, vol.311
, pp. 1471-1475
-
-
Horning, S.J.1
Rosenberg, S.A.2
-
9
-
-
33644677932
-
New treatment options have changed the survival of patients with follicular lymphoma
-
Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-8452
-
(2005)
J Clin Oncol
, vol.23
, pp. 8447-8452
-
-
Fisher, R.I.1
Leblanc, M.2
Press, O.W.3
-
10
-
-
35748934779
-
Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
-
Kang TY, Rybicki LA, Bolwell BJ, et al. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 2007;40:973-978
-
(2007)
Bone Marrow Transplant
, vol.40
, pp. 973-978
-
-
Kang, T.Y.1
Rybicki, L.A.2
Bolwell, B.J.3
-
11
-
-
0033570991
-
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
-
Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-3333 (Pubitemid 29536125)
-
(1999)
Blood
, vol.94
, Issue.10
, pp. 3325-3333
-
-
Freedman, A.S.1
Neuberg, D.2
Mauch, P.3
Soiffer, R.J.4
Anderson, K.C.5
Fisher, D.C.6
Schlossman, R.7
Alyea, E.P.8
Takvorian, T.9
Jallow, H.10
Kuhlman, C.11
Ritz, J.12
Nadler, L.M.13
Gribben, J.G.14
-
12
-
-
0026409856
-
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
-
Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-1533
-
(1991)
N Engl J Med
, vol.325
, pp. 1525-1533
-
-
Gribben, J.G.1
Freedman, A.S.2
Neuberg, D.3
-
13
-
-
0027235630
-
Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
-
Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449-3457
-
(1993)
Blood
, vol.81
, pp. 3449-3457
-
-
Gribben, J.G.1
Neuberg, D.2
Freedman, A.S.3
-
14
-
-
0642281444
-
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
-
Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-3927
-
(2003)
J Clin Oncol
, vol.21
, pp. 3918-3927
-
-
Schouten, H.C.1
Qian, W.2
Kvaloy, S.3
-
15
-
-
0033657113
-
Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
-
Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:628-632
-
(2000)
Biol Blood Marrow Transplant
, vol.6
, pp. 628-632
-
-
Flinn, I.W.1
O'Donnell, P.V.2
Goodrich, A.3
-
16
-
-
0032740188
-
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
-
Buckstein R, Imrie K, Spaner D, et al. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999;26:115-122
-
(1999)
Semin Oncol
, vol.26
, pp. 115-122
-
-
Buckstein, R.1
Imrie, K.2
Spaner, D.3
-
17
-
-
67349249726
-
Rituximab purging and maintenance combined with auto-SCT: Long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma
-
Hicks LK, Woods A, Buckstein R, et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009;43:701-708
-
(2009)
Bone Marrow Transplant
, vol.43
, pp. 701-708
-
-
Hicks, L.K.1
Woods, A.2
Buckstein, R.3
-
18
-
-
9444247655
-
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study
-
Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004;15:1691-1698
-
(2004)
Ann Oncol
, vol.15
, pp. 1691-1698
-
-
Brugger, W.1
Hirsch, J.2
Grunebach, F.3
-
19
-
-
0037480740
-
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
-
Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749-755
-
(2003)
Blood
, vol.102
, pp. 749-755
-
-
Gianni, A.M.1
Magni, M.2
Martelli, M.3
-
20
-
-
63949086667
-
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: A 10-year update of the R-HDS regimen
-
Magni M, Di Nicola M, Carlo-Stella C, et al. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2009;43:509-511
-
(2009)
Bone Marrow Transplant
, vol.43
, pp. 509-511
-
-
Magni, M.1
Di Nicola, M.2
Carlo-Stella, C.3
-
21
-
-
53449089095
-
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
-
Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693
-
(2008)
Blood
, vol.112
, pp. 2687-2693
-
-
Geisler, C.H.1
Kolstad, A.2
Laurell, A.3
-
22
-
-
27244452464
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
-
Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023
-
(2005)
J Clin Oncol
, vol.23
, pp. 7013-7023
-
-
Romaguera, J.E.1
Fayad, L.2
Rodriguez, M.A.3
-
23
-
-
18144382284
-
Hematopoietic stem cell transplantation in mantle cell lymphoma
-
Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005;16:618-624
-
(2005)
Ann Oncol
, vol.16
, pp. 618-624
-
-
Ganti, A.K.1
Bierman, P.J.2
Lynch, J.C.3
-
24
-
-
70349331498
-
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma
-
Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27:4365-4370
-
(2009)
J Clin Oncol
, vol.27
, pp. 4365-4370
-
-
Andersen, N.S.1
Pedersen, L.B.2
Laurell, A.3
-
25
-
-
46949100899
-
R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma
-
Lim SH, Esler WV, Periman PO, et al. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma. Br J Haematol 2008;142:482-484
-
(2008)
Br J Haematol
, vol.142
, pp. 482-484
-
-
Lim, S.H.1
Esler, W.V.2
Periman, P.O.3
-
26
-
-
0036178669
-
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma
-
Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002;29:56-69
-
(2002)
Semin Oncol
, vol.29
, pp. 56-69
-
-
Mangel, J.1
Buckstein, R.2
Imrie, K.3
-
27
-
-
76749087670
-
Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: Extended follow-up of a matched pair analysis
-
abstract 3051
-
Hicks L, Connors JM, Mangel J, et al. Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: Extended follow-up of a matched pair analysis. Blood 2006;108:abstract 3051
-
(2006)
Blood
, vol.108
-
-
Hicks, L.1
Connors, J.M.2
Mangel, J.3
-
28
-
-
46749102137
-
European MCL Network: An update on current first line trials
-
abstract 388
-
Dreyling M, Hoster E, Hermine O, et al. European MCL Network: an update on current first line trials. Blood 2007;110:abstract 388
-
(2007)
Blood
, vol.110
-
-
Dreyling, M.1
Hoster, E.2
Hermine, O.3
-
29
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
-
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545
-
(1995)
N Engl J Med
, vol.333
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
-
30
-
-
9144266912
-
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
-
Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777-783
-
(2004)
Blood
, vol.103
, pp. 777-783
-
-
Horwitz, S.M.1
Negrin, R.S.2
Blume, K.G.3
-
31
-
-
0036124560
-
Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GMCSF or radiotherapy and consolidation chemotherapy
-
Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GMCSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002;29:303-312
-
(2002)
Bone Marrow Transplant
, vol.29
, pp. 303-312
-
-
Rapoport, A.P.1
Meisenberg, B.2
Sarkodee-Adoo, C.3
-
32
-
-
0035194993
-
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
-
Ladetto M, Zallio F, Vallet S, et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001;15:1941-1949
-
(2001)
Leukemia
, vol.15
, pp. 1941-1949
-
-
Ladetto, M.1
Zallio, F.2
Vallet, S.3
-
33
-
-
33745982067
-
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
-
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127
-
(2006)
J Clin Oncol
, vol.24
, pp. 3121-3127
-
-
Habermann, T.M.1
Weller, E.A.2
Morrison, V.A.3
-
34
-
-
68949089562
-
R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study
-
abstract 8509
-
Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009;27:abstract 8509
-
(2009)
J Clin Oncol
, vol.27
-
-
Gisselbrecht, C.1
Glass, B.2
Mounier, N.3
-
35
-
-
38549158415
-
B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period
-
Lim SH, Esler WV, Zhang Y, et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 2008;49:152-153
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 152-153
-
-
Lim, S.H.1
Esler, W.V.2
Zhang, Y.3
-
36
-
-
0037082494
-
Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab
-
Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-1488
-
(2002)
Blood
, vol.99
, pp. 1486-1488
-
-
Goldberg, S.L.1
Pecora, A.L.2
Alter, R.S.3
-
37
-
-
0027057483
-
Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data
-
Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992;10:1690-1695
-
(1992)
J Clin Oncol
, vol.10
, pp. 1690-1695
-
-
Chopra, R.1
Goldstone, A.H.2
Pearce, R.3
-
38
-
-
9444272217
-
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry
-
Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797-3803
-
(2004)
Blood
, vol.104
, pp. 3797-3803
-
-
Freytes, C.O.1
Loberiza, F.R.2
Rizzo, J.D.3
-
39
-
-
40649116201
-
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome
-
Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418-425
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 418-425
-
-
Armand, P.1
Kim, H.T.2
Ho, V.T.3
-
40
-
-
34948866783
-
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
-
Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110:2744-2748
-
(2007)
Blood
, vol.110
, pp. 2744-2748
-
-
Kahl, C.1
Storer, B.E.2
Sandmaier, B.M.3
-
41
-
-
45149097052
-
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
-
Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530-5536
-
(2008)
Blood
, vol.111
, pp. 5530-5536
-
-
Khouri, I.F.1
McLaughlin, P.2
Saliba, R.M.3
-
42
-
-
16444363534
-
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention
-
Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121-2143
-
(2005)
Oncogene
, vol.24
, pp. 2121-2143
-
-
Jazirehi, A.R.1
Bonavida, B.2
-
43
-
-
0034796371
-
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone
-
Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-809
-
(2001)
Br J Haematol
, vol.114
, pp. 800-809
-
-
Di Gaetano, N.1
Xiao, Y.2
Erba, E.3
-
44
-
-
9144253902
-
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival
-
Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004;32:28-35
-
(2004)
Exp Hematol
, vol.32
, pp. 28-35
-
-
Khouri, I.F.1
Lee, M.S.2
Saliba, R.M.3
-
45
-
-
0029112701
-
Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease
-
Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995;16:289-295
-
(1995)
Bone Marrow Transplant
, vol.16
, pp. 289-295
-
-
Schultz, K.R.1
Paquet, J.2
Bader, S.3
Hay Glass, K.T.4
-
46
-
-
66149100443
-
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
-
Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144-4152
-
(2009)
Blood
, vol.113
, pp. 4144-4152
-
-
Tam, C.S.1
Bassett, R.2
Ledesma, C.3
-
47
-
-
33645505721
-
Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations
-
Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001
-
(2006)
Blood
, vol.107
, pp. 2993-3001
-
-
Zhang, C.1
Todorov, I.2
Zhang, Z.3
-
48
-
-
14344250918
-
B Cell allogeneic responses after hematopoietic cell transplantation: Is it time to address this issue?
-
Perruche S, Kleinclauss F, Tiberghien P, Saas P. B Cell allogeneic responses after hematopoietic cell transplantation: is it time to address this issue? Transplantation 2005;79:S37-39
-
(2005)
Transplantation
, vol.79
-
-
Perruche, S.1
Kleinclauss, F.2
Tiberghien, P.3
Saas, P.4
-
49
-
-
17144455839
-
IDEC-C2B8: Results of a phase i multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
-
Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-3274
-
(1997)
J Clin Oncol
, vol.15
, pp. 3266-3274
-
-
Maloney, D.G.1
Grillo-Lopez, A.J.2
Bodkin, D.J.3
-
50
-
-
7144250528
-
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDECC2B8, rituximab) in relapsed B-cell lymphoma
-
The IDEC-C2B8 Study Group
-
Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDECC2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998;9:527-534
-
(1998)
Ann Oncol
, vol.9
, pp. 527-534
-
-
Tobinai, K.1
Kobayashi, Y.2
Narabayashi, M.3
-
51
-
-
40049096169
-
B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation
-
Iori AP, Torelli GF, De Propris MS, et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008;85:386-390
-
(2008)
Transplantation
, vol.85
, pp. 386-390
-
-
Iori, A.P.1
Torelli, G.F.2
De Propris, M.S.3
-
52
-
-
66749129586
-
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
-
Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009;145:816-824
-
(2009)
Br J Haematol
, vol.145
, pp. 816-824
-
-
Ratanatharathorn, V.1
Logan, B.2
Wang, D.3
-
53
-
-
67349172120
-
Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD
-
van Dorp S, Pietersma F, Wolfl M, et al. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009;15:671-678
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 671-678
-
-
Van Dorp, S.1
Pietersma, F.2
Wolfl, M.3
-
54
-
-
70350775454
-
Prophylactic rituximab after reduced intensity conditioning transplantation results in low chronic GVHD
-
abstract 466
-
Arai S, Sahaf B, Jones C, et al. Prophylactic rituximab after reduced intensity conditioning transplantation results in low chronic GVHD. Blood 2008;112:abstract 466
-
(2008)
Blood
, vol.112
-
-
Arai, S.1
Sahaf, B.2
Jones, C.3
-
55
-
-
54449093967
-
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
-
Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912-4920
-
(2008)
J Clin Oncol
, vol.26
, pp. 4912-4920
-
-
Sorror, M.L.1
Storer, B.E.2
Sandmaier, B.M.3
-
56
-
-
9444239769
-
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
-
Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542
-
(2004)
Blood
, vol.104
, pp. 3535-3542
-
-
Maris, M.B.1
Sandmaier, B.M.2
Storer, B.E.3
-
57
-
-
9144219634
-
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
-
DOI 10.1182/blood-2003-03-0984
-
Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004;103:353-359 (Pubitemid 38035116)
-
(2004)
Blood
, vol.103
, Issue.1
, pp. 353-359
-
-
Miklos, D.B.1
Kim, H.T.2
Zorn, E.3
Hochberg, E.P.4
Guo, L.5
Mattes-Ritz, A.6
Viatte, S.7
Soiffer, R.J.8
Antin, J.H.9
Ritz, J.10
-
58
-
-
20144386800
-
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
-
Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-2978
-
(2005)
Blood
, vol.105
, pp. 2973-2978
-
-
Miklos, D.B.1
Kim, H.T.2
Miller, K.H.3
-
59
-
-
0037310430
-
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome
-
Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-171
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 168-171
-
-
Mariette, X.1
Roux, S.2
Zhang, J.3
-
60
-
-
10744224617
-
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations
-
Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-3486
-
(2003)
Arthritis Rheum
, vol.48
, pp. 3475-3486
-
-
Stohl, W.1
Metyas, S.2
Tan, S.M.3
-
61
-
-
31044440282
-
Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes
-
DOI 10.1002/art.21526
-
Matsushita T, Hasegawa M, Yanaba K, et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201 (Pubitemid 43122202)
-
(2006)
Arthritis and Rheumatism
, vol.54
, Issue.1
, pp. 192-201
-
-
Matsushita, T.1
Hasegawa, M.2
Yanaba, K.3
Kodera, M.4
Takehara, K.5
Sato, S.6
-
62
-
-
35948938957
-
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
-
Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107-6114
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6107-6114
-
-
Sarantopoulos, S.1
Stevenson, K.E.2
Kim, H.T.3
-
63
-
-
65549132114
-
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
-
Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009;113:3865-3874
-
(2009)
Blood
, vol.113
, pp. 3865-3874
-
-
Sarantopoulos, S.1
Stevenson, K.E.2
Kim, H.T.3
-
64
-
-
33745964855
-
Rituximab for steroid-refractory chronic graft-versus-host disease
-
DOI 10.1182/blood-2006-01-0233
-
Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-762 (Pubitemid 44061381)
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 756-762
-
-
Cutler, C.1
Miklos, D.2
Kim, H.T.3
Treister, N.4
Woo, S.-B.5
Bienfang, D.6
Klickstein, L.B.7
Levin, J.8
Miller, K.9
Reynolds, C.10
Macdonell, R.11
Pasek, M.12
Lee, S.J.13
Ho, V.14
Soiffer, R.15
Antin, J.H.16
Ritz, J.17
Alyea, E.18
-
65
-
-
77950454469
-
Rituximab infusion two months after HCT decreases alloreactive B cell responses while recipient plasma cells persist
-
abstract 2234
-
Sahaf B, Boiko J, Chen G, et al. Rituximab infusion two months after HCT decreases alloreactive B cell responses while recipient plasma cells persist. Blood 2008;112:abstract 2234
-
(2008)
Blood
, vol.112
-
-
Sahaf, B.1
Boiko, J.2
Chen, G.3
-
66
-
-
0034662901
-
Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease
-
Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275-279
-
(2000)
Ann Intern Med
, vol.133
, pp. 275-279
-
-
Ratanatharathorn, V.1
Carson, E.2
Reynolds, C.3
-
67
-
-
1542472753
-
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody
-
Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-511
-
(2003)
Biol Blood Marrow Transplant
, vol.9
, pp. 505-511
-
-
Ratanatharathorn, V.1
Ayash, L.2
Reynolds, C.3
-
68
-
-
4944225787
-
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease
-
Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004;104:2603-2606
-
(2004)
Blood
, vol.104
, pp. 2603-2606
-
-
Canninga-Van Dijk, M.R.1
Van Der Straaten, H.M.2
Fijnheer, R.3
-
69
-
-
33644984521
-
Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
-
Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-173
-
(2006)
Leukemia
, vol.20
, pp. 172-173
-
-
Okamoto, M.1
Okano, A.2
Akamatsu, S.3
-
70
-
-
34547185482
-
Treatment of refractory chronic GVHD with rituximab: A GITMO study
-
Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273-277
-
(2007)
Bone Marrow Transplant
, vol.40
, pp. 273-277
-
-
Zaja, F.1
Bacigalupo, A.2
Patriarca, F.3
-
71
-
-
44449132292
-
Rituximab as salvage therapy for refractory chronic GVHD
-
Mohty M, Marchetti N, El-Cheikh J, et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909-911
-
(2008)
Bone Marrow Transplant
, vol.41
, pp. 909-911
-
-
Mohty, M.1
Marchetti, N.2
El-Cheikh, J.3
-
72
-
-
56049118902
-
Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab
-
von Bonin M, Oelschlagel U, Radke J, et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875-879
-
(2008)
Transplantation
, vol.86
, pp. 875-879
-
-
Von Bonin, M.1
Oelschlagel, U.2
Radke, J.3
-
73
-
-
0032541811
-
Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
-
Faye A, Van Den Abeele T, Peuchmaur M, et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998;352:1285
-
(1998)
Lancet
, vol.352
, pp. 1285
-
-
Faye, A.1
Van Den Abeele, T.2
Peuchmaur, M.3
-
74
-
-
33645340322
-
Management of patients with post-transplant lymphoproliferative disorder: The role of rituximab
-
Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259-269
-
(2006)
Transpl Int
, vol.19
, pp. 259-269
-
-
Svoboda, J.1
Kotloff, R.2
Tsai, D.E.3
-
75
-
-
0033997255
-
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
-
Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(Suppl 1):113-116
-
(2000)
Ann Oncol
, vol.11
, Issue.SUPPL. 1
, pp. 113-116
-
-
Milpied, N.1
Vasseur, B.2
Parquet, N.3
-
76
-
-
9144236279
-
Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy
-
Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004;77:76-84
-
(2004)
Transplantation
, vol.77
, pp. 76-84
-
-
Clave, E.1
Agbalika, F.2
Bajzik, V.3
-
77
-
-
33644880019
-
Preemptive diagnosis and treatment of Epstein--Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: An approach in development
-
Weinstock DM, Ambrossi GG, Brennan C, et al. Preemptive diagnosis and treatment of Epstein--Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539-546
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 539-546
-
-
Weinstock, D.M.1
Ambrossi, G.G.2
Brennan, C.3
-
78
-
-
70349658396
-
Outcome of treatment of Epstein--Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases
-
Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein--Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009;11:383-392
-
(2009)
Transpl Infect Dis
, vol.11
, pp. 383-392
-
-
Styczynski, J.1
Einsele, H.2
Gil, L.3
Ljungman, P.4
-
79
-
-
77952193264
-
Prophylactic use of rituximab to prevent EBV reactivation following HSCT in patients with inherited metabolic storage diseases
-
abstract 753
-
Rovelli A, Corti P, Balduzzi A, et al. Prophylactic use of rituximab to prevent EBV reactivation following HSCT in patients with inherited metabolic storage diseases. Bone Marrow Transplant 2004;33:abstract 753
-
(2004)
Bone Marrow Transplant
, vol.33
-
-
Rovelli, A.1
Corti, P.2
Balduzzi, A.3
-
80
-
-
77952112599
-
Rituximab prophylaxis of EBV reactivation after alternative donor transplants following anti-thymocyte globulin-based conditioning regimens
-
abstract 2232
-
Bacigalupo A, Dominietto A, Soracco M, et al. Rituximab prophylaxis of EBV reactivation after alternative donor transplants following anti-thymocyte globulin-based conditioning regimens. Blood 2008;112:abstract 2232
-
(2008)
Blood
, vol.112
-
-
Bacigalupo, A.1
Dominietto, A.2
Soracco, M.3
-
81
-
-
77952170347
-
IgG allotypes reveal that antimicrobial humoral immunity persists after reduced-intensity hematopoietic cell transplantation
-
abstract 349
-
Boiko JR, Sahaf B, Mueller AMS, et al. IgG allotypes reveal that antimicrobial humoral immunity persists after reduced-intensity hematopoietic cell transplantation. Blood 2008;112:abstract 349
-
(2008)
Blood
, vol.112
-
-
Boiko, J.R.1
Sahaf, B.2
Mueller, A.M.S.3
|